BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Provided By GlobeNewswire
Last update: Feb 13, 2025
Focus on Patients with Elevated Markers of Heart Stress and Inflammation
Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery
Read more at globenewswire.comNASDAQ:BCDA (9/4/2025, 8:00:01 PM)
2.04
0 (0%)
Find more stocks in the Stock Screener
